Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine

Robert D. Gibbons, Kwan Hur, C. Hendricks Brown, John M. Davis, J. John Mann

Research output: Contribution to journalArticle

179 Citations (Scopus)

Abstract

Context: Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression. Objective: To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations. Data Sources: Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride. Study Selection: All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine. Data Extraction: Children's Depression Rating Scale-Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine. Data Synthesis: Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6% greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1%) and remission rates (30.1%), with adult differences generally in the 15.6% (remission) to 21.4% (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5% greater rate of improvement, 9.9% for response and 6.5% for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction. Conclusions: To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.

Original languageEnglish
Pages (from-to)572-579
Number of pages8
JournalArchives of General Psychiatry
Volume69
Issue number6
DOIs
StatePublished - Jun 1 2012

Fingerprint

Fluoxetine
Antidepressive Agents
Geriatrics
Randomized Controlled Trials
Placebos
Depression
Major Depressive Disorder
Age Groups
Population
Information Storage and Retrieval
Venlafaxine Hydrochloride
Antidepressants
Randomized Controlled Trial
Placebo
Pharmaceutical Preparations
Meta-Analysis
Therapeutics
Research
Remission

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Arts and Humanities (miscellaneous)

Cite this

Benefits from antidepressants : Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. / Gibbons, Robert D.; Hur, Kwan; Brown, C. Hendricks; Davis, John M.; Mann, J. John.

In: Archives of General Psychiatry, Vol. 69, No. 6, 01.06.2012, p. 572-579.

Research output: Contribution to journalArticle

Gibbons, Robert D. ; Hur, Kwan ; Brown, C. Hendricks ; Davis, John M. ; Mann, J. John. / Benefits from antidepressants : Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. In: Archives of General Psychiatry. 2012 ; Vol. 69, No. 6. pp. 572-579.
@article{79a5d936620d40d38dd4e4624bfc070e,
title = "Benefits from antidepressants: Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine",
abstract = "Context: Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression. Objective: To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations. Data Sources: Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride. Study Selection: All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine. Data Extraction: Children's Depression Rating Scale-Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine. Data Synthesis: Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6{\%} greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1{\%}) and remission rates (30.1{\%}), with adult differences generally in the 15.6{\%} (remission) to 21.4{\%} (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5{\%} greater rate of improvement, 9.9{\%} for response and 6.5{\%} for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction. Conclusions: To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.",
author = "Gibbons, {Robert D.} and Kwan Hur and Brown, {C. Hendricks} and Davis, {John M.} and Mann, {J. John}",
year = "2012",
month = "6",
day = "1",
doi = "10.1001/archgenpsychiatry.2011.2044",
language = "English",
volume = "69",
pages = "572--579",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Benefits from antidepressants

T2 - Synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine

AU - Gibbons, Robert D.

AU - Hur, Kwan

AU - Brown, C. Hendricks

AU - Davis, John M.

AU - Mann, J. John

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Context: Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression. Objective: To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations. Data Sources: Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride. Study Selection: All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine. Data Extraction: Children's Depression Rating Scale-Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine. Data Synthesis: Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6% greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1%) and remission rates (30.1%), with adult differences generally in the 15.6% (remission) to 21.4% (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5% greater rate of improvement, 9.9% for response and 6.5% for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction. Conclusions: To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.

AB - Context: Some meta-analyses suggest that efficacy of antidepressants for major depression is overstated and limited to severe depression. Objective: To determine the short-term efficacy of antidepressants for treating major depressive disorder in youth, adult, and geriatric populations. Data Sources: Reanalysis of all intent-to-treat person-level longitudinal data during the first 6 weeks of treatment of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride and 21 adult trials of venlafaxine hydrochloride. Study Selection: All sponsor-conducted randomized controlled trials of fluoxetine and venlafaxine. Data Extraction: Children's Depression Rating Scale-Revised scores (youth population), Hamilton Depression Rating Scale scores (adult and geriatric populations), and estimated response and remission rates at 6 weeks were analyzed for 2635 adults, 960 geriatric patients, and 708 youths receiving fluoxetine and for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release venlafaxine. Data Synthesis: Patients in all age and drug groups had significantly greater improvement relative to control patients receiving placebo. The differential rate of improvement was largest for adults receiving fluoxetine (34.6% greater than those receiving placebo). Youths had the largest treated vs control difference in response rates (24.1%) and remission rates (30.1%), with adult differences generally in the 15.6% (remission) to 21.4% (response) range. Geriatric patients had the smallest drug-placebo differences, an 18.5% greater rate of improvement, 9.9% for response and 6.5% for remission. Immediate-release venlafaxine produced larger effects than extended-release venlafaxine. Baseline severity could not be shown to affect symptom reduction. Conclusions: To our knowledge, this is the first research synthesis in this area to use complete longitudinal person-level data from a large set of published and unpublished studies. The results do not support previous findings that antidepressants show little benefit except for severe depression. The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorder in all age groups, although more so in youths and adults compared with geriatric patients. Baseline severity was not significantly related to degree of treatment advantage over placebo.

UR - http://www.scopus.com/inward/record.url?scp=84861617489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861617489&partnerID=8YFLogxK

U2 - 10.1001/archgenpsychiatry.2011.2044

DO - 10.1001/archgenpsychiatry.2011.2044

M3 - Article

C2 - 22393205

AN - SCOPUS:84861617489

VL - 69

SP - 572

EP - 579

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 6

ER -